Wednesday 14th February 2018
|Text too small?|
Synlait Milk, the NZX-listed dairy company, has inked a new five-year supply agreement for increased volumes of packaged infant formula with its cornerstone shareholder Bright Dairy.
The agreement builds on previous supply arrangements put in place since the relationship began in 2011 and targets a fourfold increase from current volumes over the five-year term, Rakaia-based Synlait said in a statement.
The deal provides both companies with certainty around production volumes for Bright Dairy's flagship infant nutrition brand Pure Canterbury, which is sold through online and traditional channels in China. It will also help underpin Synlait's application to register Pure Canterbury with the China Food and Drug Administration as part of stricter rules aimed at lifting China's food safety standards.
"This new agreement is a positive step in our long standing partnership and we're looking forward to playing a key role in the future success of Bright Dairy's infant formula business," said Synlait managing director John Penno. "The shareholder dynamic is something we share with a number of our customers and it fosters a close relationship that focuses on the medium to long-term success for everyone involved."
China's Bright Dairy is Synlait's largest shareholder with a 39.4 percent stake. Other infant nutrition customers with a strategic shareholding include NZX-listed The a2 Milk Company and US-based Munchkin Inc.
Synlait shares last traded at $6.61 and have gained 112 percent over the past year.
No comments yet
Transpower seeks up to $125 mln in new bond ahead of November maturity
Chorus open to convergence in fixed, mobile networks, CEO McKenzie says
Metlifecare shares fall 4.8% as posts drop as first-half profit falls 66%
Chorus first-half profit drops 29% as wireless competition bites; signals job cuts in cost-cutting drive
February 26th Morning Report
CBL appoints voluntary administrators to 'preserve value' after interim liquidation
NZ dollar holds below 73 US cts as Fed chair Powell testimony comes into focus
World Week Ahead: Rate path check from Powell
RBNZ gets High Court order putting CBL Insurance into interim liquidation
MARKET CLOSE: NZ shares rise, led by Summerset, Metlifecare, Comvita falls after flagging poor season